Department of Gastroenterological Surgery, Nagoya University Graduate School of Medicine, 65 Tsurumai-Cho, Showa-Ku, Nagoya, 466-8550, Japan.
Department of Gastroenterological Surgery, Aichi Cancer Center, Nagoya, Japan.
Gastric Cancer. 2024 Nov;27(6):1331-1341. doi: 10.1007/s10120-024-01546-x. Epub 2024 Aug 22.
Large type 3 (diameter ≥ 8 cm) and type 4 gastric cancers have been arbitrarily combined in Japan as a single entity. However, whether these two types are oncologically similar remain unclear. This study aimed to clarify this issue.
In this retrospective study, we analyzed a database of 3,575 patients from nine institutions who underwent gastrectomy between 2010 and 2014. Using propensity scores to balance significant variables, we compared prognoses and tumor recurrences.
Of patients with clinical T3/T4 who underwent R0 resection, 75 and 73 had large type 3 and 4 tumors, respectively. Patients with type 4 tumors had significantly lower overall survival rates than those of patients with large type 3 tumors (hazard ratio [HR] 1.77; 95% confidence interval [CI] 1.14-2.74). However, among the large type 3 tumors, a remarkable difference in prognosis was observed between the differentiated and undifferentiated histological types. A comparison was made between large type 3 with undifferentiated phenotype and type 4, each with 39 patients after propensity score matching. Outcomes in both groups were similar in terms of overall survival (HR 1.28; 95% CI 0.73-2.25) and relapse-free survival (HR 1.34; 95% CI 0.80-2.27). No statistically significant differences were observed in the incidence of peritoneal recurrence (35.9% vs. 46.1%, P = 0.36) and lymph node recurrence (25.6% vs. 12.8%, P = 0.15).
Large type 3 tumors with undifferentiated phenotype and type 4 tumors were oncologically similar. This subgroup could be considered as a new entity for future clinical trials.
在日本,大型 3 型(直径≥8cm)和 4 型胃癌被任意组合为单一实体。然而,这两种类型在肿瘤学上是否相似尚不清楚。本研究旨在阐明这一问题。
在这项回顾性研究中,我们分析了来自 9 个机构的 3575 名患者的数据库,这些患者在 2010 年至 2014 年间接受了胃切除术。我们使用倾向评分来平衡显著变量,比较了预后和肿瘤复发情况。
在接受 R0 切除的临床 T3/T4 患者中,75 例和 73 例患者分别患有大型 3 型和 4 型肿瘤。与大型 3 型肿瘤患者相比,4 型肿瘤患者的总生存率显著降低(风险比 [HR] 1.77;95%置信区间 [CI] 1.14-2.74)。然而,在大型 3 型肿瘤中,分化型和未分化型组织学类型之间的预后存在显著差异。对 39 例大型 3 型未分化表型肿瘤和 39 例 4 型肿瘤进行倾向评分匹配后进行比较。两组患者的总生存(HR 1.28;95% CI 0.73-2.25)和无复发生存(HR 1.34;95% CI 0.80-2.27)无显著差异。腹膜复发(35.9%比 46.1%,P=0.36)和淋巴结复发(25.6%比 12.8%,P=0.15)的发生率无统计学差异。
大型 3 型未分化表型肿瘤和 4 型肿瘤在肿瘤学上相似。这一分组可被视为未来临床试验的一个新实体。